AWM
ITCI

AE Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AE Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,326
Closed -$494K – 2055
2023
Q4 		$494K Buy
+7,326
New +$421K ﹤0.01% 1445
2023
Q3 		– Sell
-16,137
Closed -$1.02M – 2090
2023
Q2 		$1.02M Buy
+16,137
New +$1.01M 0.01% 1085
2023
Q1 		– Sell
-11,137
Closed -$589K – 2021
2022
Q4 		$589K Buy
+11,137
New +$558K ﹤0.01% 1220

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AE Wealth Management's ITCI Position: Q1 2024 in Review

AE Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 7,326 shares — an estimated $494K sold.

AE Wealth Management first reported a position in ITCI in Q4 2022 and held it in 3 quarters. The position peaked at $1.02M in Q2 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • AE Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 7,326 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $494K.
  • AE Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 3 quarters.
  • AE Wealth Management's Intra-Cellular Therapies Inc. position peaked at $1.02M in Q2 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.